- Report
- October 2024
- 190 Pages
Global
From €3503EUR$3,545USD£2,915GBP
€3892EUR$3,939USD£3,239GBP
- Report
- February 2024
- 250 Pages
Global
From €4940EUR$5,000USD£4,112GBP
- Report
- November 2024
- 93 Pages
Global
From €5533EUR$5,600USD£4,605GBP
- Report
- May 2024
- 140 Pages
Global
From €6422EUR$6,499USD£5,345GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2075EUR$2,100USD£1,727GBP
€2964EUR$3,000USD£2,467GBP
- Report
- June 2024
- 200 Pages
Global
From €5499EUR$5,565USD£4,577GBP
€7855EUR$7,950USD£6,538GBP
- Report
- September 2024
- 253 Pages
Global
From €4446EUR$4,500USD£3,701GBP
- Report
- October 2024
- 183 Pages
Global
From €3503EUR$3,545USD£2,915GBP
€3892EUR$3,939USD£3,239GBP
- Report
- June 2024
- 225 Pages
Global
From €2460EUR$2,490USD£2,048GBP
- Report
- October 2024
- 187 Pages
Global
From €3503EUR$3,545USD£2,915GBP
€3892EUR$3,939USD£3,239GBP
- Report
- February 2024
- 250 Pages
Global
From €4940EUR$5,000USD£4,112GBP
- Report
- July 2024
- 125 Pages
Global
From €5879EUR$5,950USD£4,893GBP
- Report
- June 2024
- 150 Pages
Global
From €5879EUR$5,950USD£4,893GBP
- Report
- January 2024
- 200 Pages
Global
From €4940EUR$5,000USD£4,112GBP
- Report
- April 2024
- 137 Pages
Global
From €3853EUR$3,899USD£3,207GBP
- Clinical Trials
- November 2024
- 240 Pages
Global
From €2964EUR$3,000USD£2,467GBP
- Report
- August 2024
- 60 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more